The lipid mediator sphingosine 1-phosphate (S1P) regulates several cellular processes through binding to its receptors (S1P 1 -S1P 5 ), which are heterotrimeric G protein-coupled receptors. Here, we report that all S1P receptors are palmitoylated. In S1P 1 , three Cys residues in the cytoplasmic tail are palmitoylated. We examined the roles of palmitoylation of S1P 1 using model cells in which wild type S1P 1 or a non-palmitoylated mutant S1P 1 was overproduced. Compared to wild type S1P 1 , the non-palmitoylated S1P 1 exhibited similar binding affinity to the natural ligand S1P but lower affinity to the synthetic ligand FTY720 phosphate (FTY720-P), the active form of the immunomodulator FTY720.
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signaling initiated by exposure to their ligands. However, a palmitoylation site mutant of the β 2 -adrenergic receptor is hyperphosphorylated even without ligand stimulation (Moffett et al. 1993 ), yet phosphorylation is suppressed in palmitoylation mutants of the V 1a vasopressin receptor (Hawtin et al. 2001 ) and the chemokine receptor CCR5 (Kraft et al. 2001) . Therefore, it is important to determine the roles palmitoylation exerts on each individual GPCR.
The GPCRs S1P 1 through S1P 5 recognize the lipid mediator sphingosine 1-phosphate (S1P), which regulates a variety of cellular functions (Spiegel & Milstien 2003; Sanchez & Hla 2004; Kihara et al. 2007) . Of these receptors, S1P 1 is the most important physiologically, especially in the vascular and immune systems (Spiegel & Milstien 2003; Sanchez & Hla 2004; Kihara et al. 2007) . For example, S1P 1 performs a pivotal function in lymphocyte egress from the thymus and secondary lymphoid organs (Chiba et al. 2006; Kihara et al. 2007; Kihara & Igarashi 2008) . In fact, a novel therapeutic (FTY720) currently undergoing Clinical Trials as an immunomodulator (Budde et al. 2006; Chiba et al. 2006; Kihara & Igarashi 2008 ) is actually a prodrug whose active phosphorylated form, FTY720 phosphate (FTY720-P), acts as a ligand for all S1P receptors except S1P 2 (Brinkmann et al. 2002; Mandala et al. 2002) .
After ligand binding, S1P 1 is internalized, desensitizing the stimulus (Liu et al. 1999) . When the ligand is S1P, the S1P 1 receptor is recycled back to the cell surface. However, when the stimulus is FTY720-P, S1P 1 is not recycled to the plasma membrane but is degraded, resulting in a loss of the receptor at the cell surface (Gräler & Goetzl 2004; Matloubian et al. 2004; Jo et al. 2005) . To date, the molecular mechanism causing the differences between S1P and FTY720-P in internalization of S1P 1 has remained unclear.
Several post-translational modifications have been reported for S1P 1 , including phosphorylation (Watterson et al. 2002) , N-glycosylation (Kohno et al. 2002) , sulfation (Fieger et al. 2005) , and ubiquitinylation (Oo et al. 2007 ). However, palmitoylation of S1P 1 and its role have not been 5 previously examined. In the study presented here, we have demonstrated that three Cys residues in the C-terminal tail of S1P 1 are palmitoylated. We also report that palmitoylation of S1P 1 is involved in high affinity binding to FTY720-P but not to S1P, and in the downstream signaling of S1P 1 , irrespective of S1P and FTY720-P stimulation. Palmitoylation also plays a role in the internalization of S1P 1 , especially following FTY720-P stimulation. Thus, palmitoylation affects several post-stimulation processes involving S1P 1 , sometimes differently following S1P stimulation versus FTY720-P stimulation. The differential effects of palmitoylation on internalization may provide important clues for understanding the molecular mechanism of the pharmacological effects of FTY720.
Results

All S1P receptors are palmitoylated
Like other GPCRs, S1P receptors contain one to three Cys residues proximal to the last transmembrane in the C-terminal tail (Fig. 1A) . To investigate whether S1P receptors are palmitoylated, each receptor was cloned and transiently expressed in Human embryonic kidney (HEK) 293T cells as a C-terminally 3xFLAG-tagged protein. All S1P receptors were detected by immunoblotting as several bands, typically a broad upper band and sharp lower band(s) (Fig. 1B) . Different protein bands of each S1P receptor presumably represent proteins carrying different forms of glycosylation, since all S1P receptors contain potential N-glycosylation sites at their N-termini, and the N-glycosylation of S1P 1 has already been reported (Kohno et al. 2002) . To examine whether the S1P receptors carried high mannose-or complex-type N-glycosylation, we treated each protein sample with Endoglycosidase H (Endo H), which removes only high mannose-type N-glycosylation, and peptide:N-glycosidase F (PNGase F), which can remove both high mannose-and complex-types. The lower sharp bands were shifted to lower molecular weight bands upon treatment with Endo H (Fig. 1B) , indicating that these proteins are modified with high mannose-type glycosylation. On the other hand, the upper broad bands were shifted to low molecular weight bands only by treatment with PNGase F (Fig. 1B) , indicating that they were modified with complex-type glycosylation. Proteins destined to the plasma membrane, including GPCRs, are synthesized in the ER, where high mannose-type N-glycosylation occurs, then are transported to the Golgi, where the glycosylation is modified to the complex-type, and, finally, are delivered to the plasma membrane. Therefore, high mannose-type glycosylated S1P receptors may localize in the ER, while complex-type glycosylated S1P receptors may localize in the plasma membrane (or possibly in the Golgi). Detecting such substantial levels of ER-localized receptors may be due to the transient expression system, in which protein synthesis begins to increase ~24 h after transfection. The cells were transfected 24 h before use, and so the observed S1P receptor proteins 7 might have been newly synthesized.
Next, HEK 293T cells transiently expressing each S1P receptor were metabolically labeled with [ 3 H]palmitic acid. As shown in Fig. 1C , all S1P receptors were radiolabeled, although the intensities of the label varied among the receptors. Labeling efficiency was highest for S1P 1 and S1P 5 , and then for S1P 4 . The number of potential palmitoylated Cys residues in the receptor was at least partly responsible for the high labeling efficiency (S1P 1 , S1P 4 , and S1P 5 each have three), however this did not always correlate with labeling efficiency. For example, S1P 3 , which contains two potential palmitoylated Cys residues, was less efficiently labeled with [ 3 H]palmitic acid than was S1P 2 , which contains only one.
Therefore, a higher population of S1P 3 may exist in a non-palmitoylated state compared to the other S1P receptors, or S1P 3 may be depalmitoylated more rapidly. Both high mannose-type and complex-type glycosylated S1P receptors were labeled, indicating that palmitoylation, at least partly, already occurs in the ER, although the possibility that the S1P receptors are further palmitoylated or re-palmitoylated after depalmitoylation at other organelles cannot be excluded.
Palmitoylation of the S1P receptors was further confirmed by an acyl-biotinyl exchange (ABE) assay (Drisdel & Green 2004) , in which palmitic acid is removed via hydroxylamine-mediated cleavage of the palmitoyl-thioester bond and the remaining thiol group is labeled with a thiol-specific biotinylation reagent. Non-palmitoylated Cys residues were first protected by the thiol modifier N-ethyl maleimide (NEM), and so do not react with the thiol-specific biotinylation reagent. The biotinylated proteins were recovered by avidin-agarose and detected by immunoblotting. Using this method, all S1P receptors were again determined to be palmitoylated proteins (Fig. 1D ).
S1P 1 is palmitoylated on three Cys residues in the C-terminal tail
We focused on the palmitoylation of S1P 1 , since it is the physiologically most important S1P receptor.
To examine whether the Cys residues are palmitoylated as expected, we constructed S1P 1 (3CA)-3xFLAG, in which Cys-328, -329, and -331 were all changed to Ala. HEK 293T cells expressing S1P 1 -3xFLAG or S1P 1 (3CA)-3xFLAG were metabolically labeled with [ 3 H]palmitic acid.
In contrast to wild type S1P 1 , no labeling was detected in S1P 1 (3CA)-3xFLAG ( Fig. 2A ), indicating that S1P 1 is palmitoylated on these Cys residues.
We also created single and double Cys-to-Ala substituted mutants (C328A, C329A, C331A, C328/329A, C329/331A, and C328/331A), and subjected them to the ABE assay. Wild type S1P 1 -3xFLAG and all of the single and double Cys-substituted mutants were detected as palmitoylated proteins, although the triple Cys-substituted mutant (S1P 1 (3CA)-3xFLAG) was not (Fig. 2B ). The band intensities were not dependent on the number of palmitoylated Cys residues. This result is reasonable, since biotinylated proteins are logically recovered by avidin beads with nearly equal efficiency, regardless of the number of biotinylated Cys residues, and we detected them with an anti-FLAG antibody, rather than an anti-biotin antibody. In conclusion, S1P 1 is palmitoylated on Cys-328, Cys-329, and Cys-331 residues.
Palmitoylation is not involved in cell surface expression of S1P 1
Palmitoylation is required for the surface expression of some GPCRs (Escribá et al. 2007) . Therefore, we examined the intracellular localization of the wild type (S1P 1 -3xFLAG) and non-palmitoylated (S1P 1 (3CA)-3xFLAG) forms of S1P 1 . Chinese hamster ovary (CHO) cells stably expressing wild type (S1P 1 -CHO) and non-palmitoylated S1P 1 (S1P 1 (3CA)-CHO) were subjected to indirect immunofluorescent microscopy using anti-FLAG antibodies. Both wild type and non-palmitoylated S1P 1 were observed in the plasma membrane (Fig. 3A) , indicating that palmitoylation is not required for proper localization of S1P 1 . Both S1P 1 -CHO and S1P 1 (3CA)-CHO cells expressed S1P 1 to similar levels judging from immunoblotting ( Fig. 3B ) and flow cytometry (Fig. 3C ).
Palmitoylation of S1P 1 is required for efficient S1P signal transduction
We next investigated the role of palmitoylation in S1P signaling. S1P 1 couples to G i and transduces the S1P signal to several downstream pathways including the Ras/ERK, cAMP/protein kinase A, and phosphatidylinositol 3-kinase/Akt/Rac pathways (Spiegel & Milstien 2003; Sanchez & Hla 2004; Kihara et al. 2007) . We first examined the binding affinities of the wild type and 3CA mutant S1P 1 to S1P using a binding assay and [ 32 P]S1P. We found that the wild type and mutant proteins exhibited similar K d values (39.4 nM and 31.4 nM, respectively).
We next investigated the signaling activities of the wild type and non-palmitoylated mutant S1P 1 by measuring the phosphorylation levels of ERK upon treatment with various concentrations of S1P.
Maximal activation of ERK was observed in S1P 1 -CHO cells at 5 nM S1P (Fig. 4A ,B), and the EC 50
value was estimated to be 1.4 nM. Although the EC 50 value of the 3CA mutant was similar (2.4 nM), the maximal p-ERK/ERK value was determined to be 32% of that observed for the wild type S1P 1 , after subtracting background levels (those of the vector-transfected cells). These results suggest that palmitoylation affects the signaling activity of S1P 1 without affecting its binding to S1P.
When FTY720-P, the active form of the novel immunomodulating agent FTY720 (Brinkmann et al. 2002; Mandala et al. 2002) , was used for stimulation instead of S1P, wild type S1P 1 fully activated ERK even at 1 nM (EC 50 , 0.49 nM; Fig. 4C ,D). However, such full activation was observed for the 3CA mutant only at 50 nM (EC 50 , 5.2 nM; Fig. 4C,D) . Moreover, the maximal p-ERK/ERK value was ~1/2 that of the wild type S1P 1 . Thus, although palmitoylation affects the signaling activity of S1P 1 similarly after S1P or FTY720-P stimulation, it affects only the high affinity binding of S1P 1 to FTY720-P, and has little or no apparent effect on S1P 1 binding to S1P.
We also examined the kinetics of ERK activation upon treatment with S1P. Phosphorylation of ERK reached maximal levels within 3 min in S1P 1 -CHO cells and then gradually decreased (Fig. 4E,F ).
Non-palmitoylated S1P 1 also activated ERK with similar kinetics, but p-ERK levels in the S1P 1 (3CA)-CHO cells were lower than those in the S1P 1 -CHO cells until 20 min post-stimulation ( Fig. 
4E,F).
Stimulated S1P 1 induces cell migration toward S1P by activating the small GTPase Rac, via phosphatidylinositol 3-kinase (Okamoto et al. 2000) . We next investigated the ability of non-palmitoylated S1P 1 to promote cell migration, using a modified Boyden chamber. Inclusion of S1P
in the lower chamber significantly stimulated the cell migration of the S1P 1 -CHO cells, but non-palmitoylated S1P 1 was less active (Fig. 4G ). The number of migrated S1P 1 (3CA)-CHO cells was ~25% that of the S1P 1 -CHO cells (Fig. 4G ). These results also suggest that palmitoylation is needed for efficient signaling of S1P 1 .
Palmitoylation affects internalization of S1P 1
After stimulation, S1P 1 is rapidly internalized (Liu et al. 1999) . We compared the internalization of wild type and non-palmitoylated S1P 1 by flow cytometry. The overall amount of wild type S1P 1 internalized was greater than that of non-palmitoylated S1P 1 at any time point examined, although a statistically significant difference was observed only at 60 min post-stimulation (Fig. 5A ). We also investigated the effect of palmitoylation on the internalization of S1P 1 induced by FTY720-P. As reported previously (Gräler & Goetzl 2004; Matloubian et al. 2004; Jo et al. 2005) , FTY720-P stimulated the internalization of S1P 1 more efficiently than S1P did (Fig. 5B) . The effect of stimulation on non-palmitoylated S1P 1 versus S1P 1 was likewise more pronounced with FTY720-P (Fig. 5B) .
Phosphorylation of the C-terminal tail in S1P 1 by G protein-coupled receptor kinases (GRKs)
facilitates binding of the adaptor protein β-arrestin, which then induces receptor desensitization and endocytosis (Watterson et al. 2002; Oo et al. 2007) . To investigate whether retarded internalization of non-palmitoylated S1P 1 was due to lowered phosphorylation, we performed [ 32 P]orthophosphate labeling. After a 5 min treatment with S1P, phosphorylation of wild type S1P 1 was increased in a concentration-dependent manner, reaching nearly maximum levels with 10 nM S1P (Fig. 6A,B) . A similar dose-dependent curve was observed for non-palmitoylated S1P 1 (Fig. 6A,B) . However, when FTY720-P was used, the wild type S1P 1 was phosphorylated at the maximum level even at 1 nM, whereas maximal phosphorylation of the 3CA mutant required 10 nM, and its phosphorylation level was ~2/3 that of wild type S1P 1 (Fig. 6A,B) .
We also investigated the kinetics of phosphorylation for wild type and non-palmitoylated S1P 1 following stimulation with S1P or FTY720-P. In general, phosphorylation of wild type S1P 1 and non-palmitoylated S1P 1 increased over 60 min post-stimulation (Fig. 6C,D) . However, following treatment with FTY720-P, although both proteins were phosphorylated, the phosphorylation levels for non-palmitoylated S1P 1 were lower than those for wild type S1P 1 (Fig. 6C,D) . No difference in phosphorylation levels between wild type and non-palmitoylated S1P 1 were apparent following S1P
treatment. This is consistent with the small difference noted in the internalization of the proteins (Fig.   5A ), indicating some correlation between the phosphorylation levels and internalized amounts.
Palmitoylation of S1P 1 is increased upon treatment with S1P
It has been reported that in some GPCRs the state of palmitoylation is altered upon ligand treatment (Moffett et al. 1993; Hawtin et al. 2001) . Therefore, we next performed [ 3 H]palmitic acid labeling in the presence or absence of S1P using S1P 1 -CHO cells. In the absence of S1P stimulation, the amount of labeled S1P 1 was unchanged over time (Fig. 7A ). In contrast, labeling was enhanced by increasing the length of S1P treatment (Fig. 7 A) . Note that most S1P 1 in S1P 1 -CHO cells is already localized in the plasma membrane (Fig. 3A) and has undergone complex-type glycosylation. Therefore, palmitoylation following treatment with S1P occurs in the plasma membrane.
To determine whether this increase in S1P 1 palmitoylation could be attributed to direct activation of the receptor or to an indirect effect mediated by some non-receptor, we performed additional The S1P-dependent increase in the S1P 1 palmitoylation was indeed inhibited by pertussis toxin (Fig. 7B) . Thus, it is most likely that binding of the ligand to S1P 1 induces a conformational change in the structure, rendering it susceptible to palmitoylation.
Discussion
In the presented study, we determined that all S1P receptors are palmitoylated (Fig. 1C, D) . Even S1P receptors with high mannose-type glycosylation are palmitoylated (Fig. 1B, C, D) , so palmitoylation would seem to have already occurred in the ER. However, S1P 1 , at least, is also palmitoylated in other organelles. Palmitoylation of complex-type glycosylated S1P 1 , localized in the plasma membrane, was increased upon treatment with S1P (Fig. 7A) . Therefore, S1P 1 in the plasma membrane seems to be subjected to a palmitoylation/depalmitoylation cycle. This cycle may be regulated during receptor activation, desensitization, internalization, and/or recycling.
Palmitoylation does not cause a large change in the affinity of S1P 1 toward S1P (wild type S1P 1 : However, S1P 1 binding affinities toward FTY720-P seem to be affected greatly by palmitoylation, judging from the EC 50 value for ERK activation (wild type S1P 1 : 0.5 nM; 3CA mutant: 5.2 nM). It is possible that the insertion into the membrane of the palmitic acid moieties attached to the C-terminal tail of S1P 1 , which generates an additional intracellular loop in S1P 1 , may induce a local conformational change in the ligand binding site.
Although many GPCRs are known to be palmitoylated, the roles of their palmitoylation vary (Qanbar & Bouvier 2003; Escribá et al. 2007) . For S1P 1 , palmitoylation affects downstream signaling pathways (Fig. 4) irrespective of whether S1P or FTY720-P is the ligand. The maximum levels of p-ERK were significantly lower in cells overproducing the non-palmitoylated mutant S1P 1 compared to those overproducing the wild type S1P 1 (Fig. 4A-D) . Heterotrimeric G proteins (Gαβγ) are attached to the membrane via lipid modifications on Gα and Gγ (Escribá et al. 2007) . It is possible that palmitoylation of S1P 1 increases its affinity for the heterotrimeric G proteins through interactions with their lipid moieties. Alternatively, palmitoylation may cause a local conformational change that affects the interactions between S1P 1 and heterotrimeric G proteins.
Like other GPCRs, ligand stimulation induces a conformational change in S1P 1 , which aids not only in the GDP-GTP exchange of the heterotrimeric G protein α subunit, but also the availability of the receptor for phosphorylation by GRK and β-arrestin recruitment. Several lines of evidence suggest that S1P-bound S1P 1 and FTY720-P-bound S1P 1 differ in structure. For example, following treatment with S1P, internalized S1P 1 is recycled back to the cell surface, yet treatment with FTY720-P causes ubiquitination of S1P 1 and degradation (Gräler & Goetzl 2004; Matloubian et al. 2004; Jo et al. 2005) .
Therefore, ubiquitin ligase may recognize the structure of S1P 1 induced by FTY720-P but not that induced by S1P. These differences are thought to be responsible for the pharmacological effects of FTY720. However, the molecular mechanism behind the difference in the fate of S1P 1 following treatment with S1P and FTY720-P has been completely unclear. We found only a small difference in the internalization of the wild type and non-palmitoylated mutant S1P 1 upon treatment with S1P ( Fig.   5A ), in contrast to significant differences observed with FTY720-P treatment (Fig. 5B) . Thus, palmitoylation affects the internalization of S1P 1 differently when binding S1P or FTY720-P.
Phosphorylation of the mutant S1P 1 was also reduced compared to that of wild type S1P 1 following treatment with FTY720-P but not with S1P (Fig. 6) . The differential effects of palmitoylation on internalization and phosphorylation provide important clues in understanding the molecular mechanism of the pharmacological effects of FTY720. We speculate that a combination of FTY720-P binding by S1P 1 and palmitoylation of S1P 1 causes the creation of high affinity binding sites for GRKs and putative ubiquitin ligases.
Although palmitoylation was first recognized over 30 years ago, identification of the responsible enzymes, palmitoyltransferases (PATs), was only recently achieved. In 2002, two yeast proteins containing the Cys-rich domain and conserved signature motif identifying them as DHHC proteins were determined to be PATs; Erf2 and Akr1 were found to palmitoylate Ras and the casein kinase Yck2, respectively (Lobo et al. 2002; Roth et al. 2002) 
Plasmids
The pCE-puro 3xFLAG-4 plasmid is a derivative of the pCE-puro vector and is designed to produce a C-terminal triple FLAG (3xFLAG)-tagged protein. Each pCE-puro S1P x -3xFLAG plasmid (with x representing the S1P receptor number) encodes a human S1P receptor tagged with 3xFLAG at its C-terminus. The genes of the S1P receptors were amplified by PCR using appropriate templates (S1P 1 , human spleen cDNA (Clontech, Takara Bio, Shiga, Japan); S1P 2 and S1P 3 , HEK 293T cDNA; S1P 4 , human leukocyte cDNA (Clontech, Takara Bio); and S1P 5 , human lung cDNA (Clontech, Takara Bio)) and primers (for S1P 1 , EcoRI-BamHI (S1P 3 and S1P 5 ) or EcoRI-BglII (S1P 4 ) fragments of the resulting plasmids were cloned into the pCE-puro 3xFLAG-4 vector, generating the respective pCE-puro S1P x -3xFLAG plasmids.
The pCE-puro S1P 1 (C328A)-3xFLAG, pCE-puro S1P 1 (C329A)-3xFLAG, pCE-puro S1P 1 (C331A)-3xFLAG, pCE-puro S1P 1 (C328/329A)-3xFLAG, pCE-puro S1P 1 (C329/331A)-3xFLAG, pCE-puro S1P 1 (C328/331A)-3xFLAG, and pCE-puro S1P 1 (3CA)-3xFLAG plasmids encode
Cys-to-Ala substituted S1P 1 mutants. These plasmids were constructed from the pCE-puro S1P 1 -3xFLAG plasmid by site-directed mutagenesis using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Two primers with complementary sequences were used for each mutagenesis. The sense primers used were, for pCE-puro S1P 1 (C328A)-3xFLAG, 5'-CATCCGGATCATGTCCGCCTGCAAGTGCCCGAGCG-3'; for pCE-puro S1P 1 (C329A)-3xFLAG, 5'-CCGGATCATGTCCTGCGCCAAGTGCCCGAGCGGAG-3'; for pCE-puro S1P 1 (C331A)-3xFLAG, 5'-CATGTCCTGCTGCAAGGCCCCGAGCGGAGACTCTG-3';
for pCE-puro S1P 1 (C328/329A)-3xFLAG, 5'-CATCCGGATCATGTCCGCCGCCAAGTGCCCGAGCG-3'; for pCE-puro S1P 1 (C328/331A)-3xFLAG, 5'-CATCCGGATCATGTCCGCCTGCAAGGCCCCGAGCG-3'; for pCE-puro S1P 1 (C329/331A)-3xFLAG, 5'-CCGGATCATGTCCTGCGCCAAGGCCCCGAGCGGAG-3'; and for S1P 1 (3CA)-3xFLAG, 5'-CCGGATCATGTCCGCCGCCAAGGCCCCGAGCGGAGACTC-3'.
Production of stable transformants
To obtain stable transformants of the S1P 1 -3xFLAG or S1P 1 (3CA)-3xFLAG gene, the pCE-puro S1P 1 -3xFLAG or pCE-puro S1P 1 (3CA)-3xFLAG plasmid was transfected into CHO cells. Cells were subjected to puromycin selection at 10 µg/mL. One stable transformant for each plasmid, termed S1P 1 -CHO and S1P 1 (3CA)-CHO, expressed the highest level of S1P 1 -3xFLAG and S1P 1 (3CA)-3xFLAG, respectively, among the isolated clones. Although we present only the results obtained using S1P 1 -CHO and S1P 1 (3CA)-CHO cells here, other clones also tested gave similar results.
For use as a control, Vector-CHO cells were similarly obtained using the pCE-puro 3xFLAG-4 vector. mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.1% sodium deoxycholate), and the resulting total cell lysates were subjected to immunoprecipitation with anti-FLAG M2 agarose beads (Sigma). Beads were washed with RIPA buffer twice and with 10 mM Tris-HCl (pH 8.0) once, then proteins were eluted with 2x SDS sample buffer (125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 10%
In vivo labeling experiments
2-mercapoethanol, and a trace amount of bromophenol blue). Proteins were separated by SDS-PAGE and detected by autoradiography.
Deglycosylation of proteins
Endo H and PNGase F were purchased from New England Biolabs (Beverly, MA). Cells were washed
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with PBS twice, suspended in buffer A (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, and 10% 2-mercaptoethanol), and sonicated. After a 5 min incubation at 37 ˚C, samples were centrifuged at 17,400 x g for 5 min at room temperature. The supernatant was subjected to deglycosylation by EndoH or PNGase F according to the manufacturer's instructions.
Immunoblotting
Immunoblotting was performed as described previously . Anti-FLAG M2 (1 µg/mL; Stratagene), anti-extracellular signal-regulated kinase (ERK; p44/42 MAP kinase) (1:1000 dilution; Cell Signaling Technology, Beverly, MA), and anti-phospho-ERK (p-ERK) (200 ng/mL; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were used as primary antibodies.
HRP-conjugated anti-mouse or anti-rabbit IgG F(ab') 2 fragment (both from GE Healthcare Bio-Sciences, Piscataway, NJ, and diluted 1:7500) were used as secondary antibodies. Labeling was detected using ECL TM Reagents or an ECL plus System for Western Blotting Detection (both from GE Healthcare).
Immunofluorescence microscopy
Microscopic immunofluorescence analysis was performed as described previously (Ogawa et al. 2003) with anti-FLAG M2 antibodies (0.5 µg/mL) and Alexa Fluor 488 goat anti-mouse IgG (H+L) conjugated antibody (5 µg/mL, Molecular Probes, Invitrogen). The stained cells were analyzed by fluorescence microscopy (Axioskop 2 PLUS; Carl Zeiss, Oberkochen, Germany). 
ABE Assay
An ABE assay was done as described elsewhere with modifications (Drisdel & Green 2004) . Cells were washed twice with PBS and lysed on ice using RIPA buffer containing 1x Complete transfected with pCE-puro 3xFLAG-4 (vector; Vec), pCE-puro S1P 1 -3xFLAG (wild type; WT), or pCE-puro S1P 1 (3CA)-3xFLAG (S1P 1 (3CA); 3CA) were labeled with 0. or its derivatives encoding wild type or the indicated Cys-to-Ala substituted mutant of S1P 1 -3xFLAG.
Twenty-four hours after transfection, total cell lysates were prepared and analyzed by ABE assay as in cells were incubated for 12 h with F-12 medium containing charcoal-treated FBS, then for another 12 h with F-12 medium. Cells were then stained with anti-S1P 1 antibodies and subjected to flow cytometry.
Vec, vector; WT, wild type S1P 1 ; 3CA, S1P 1 (3CA). Statistically significant differences are indicated (p<0.05; Student's t-test). Vec, vector; WT, wild type S1P 1 ; 3CA, S1P 1 (3CA).
Figure 5
Palmitoylation affects the internalization of S1P 1 stimulated by FTY720-P. S1P 1 -CHO and S1P 1 (3CA)-CHO cells were incubated for 12 h with F-12 medium containing charcoal-treated FBS, then for another 12 h with F-12 medium. After a 1 h treatment with 10 µg/mL cycloheximide to inhibit protein synthesis, the cells were stimulated for 10 min (arrows) with 200 nM S1P (A) or FTY720-P (B).
Cells were washed with F-12 medium containing 4 mg/mL fatty acid-free BSA, suspended in the same medium (t=0), and incubated for 15, 30, and 60 min at 37 ˚C. Cells were then stained with anti-S1P 1
